284 related articles for article (PubMed ID: 25648629)
1. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.
Carboni E; Lingor P
Metallomics; 2015 Mar; 7(3):395-404. PubMed ID: 25648629
[TBL] [Abstract][Full Text] [Related]
2. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
3. Pathological role of lipid interaction with α-synuclein in Parkinson's disease.
Suzuki M; Sango K; Wada K; Nagai Y
Neurochem Int; 2018 Oct; 119():97-106. PubMed ID: 29305919
[TBL] [Abstract][Full Text] [Related]
4. Coordination and redox properties of copper interaction with α-synuclein.
Valensin D; Dell'Acqua S; Kozlowski H; Casella L
J Inorg Biochem; 2016 Oct; 163():292-300. PubMed ID: 27112900
[TBL] [Abstract][Full Text] [Related]
5. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol-3,4,5-trisphosphate interacts with alpha-synuclein and initiates its aggregation and formation of Parkinson's disease-related fibril polymorphism.
Choong CJ; Aguirre C; Kakuda K; Beck G; Nakanishi H; Kimura Y; Shimma S; Nabekura K; Hideshima M; Doi J; Yamaguchi K; Nakajima K; Wadayama T; Hayakawa H; Baba K; Ogawa K; Takeuchi T; Badawy SMM; Murayama S; Nagano S; Goto Y; Miyanoiri Y; Nagai Y; Mochizuki H; Ikenaka K
Acta Neuropathol; 2023 May; 145(5):573-595. PubMed ID: 36939875
[TBL] [Abstract][Full Text] [Related]
7. RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies.
Poggiolini I; Erskine D; Vaikath NN; Ponraj J; Mansour S; Morris CM; El-Agnaf OMA
Biomolecules; 2021 May; 11(6):. PubMed ID: 34072869
[TBL] [Abstract][Full Text] [Related]
8. Ignored avenues in alpha-synuclein associated proteopathy.
Chowhan RK; Mittal S; Dar TA; Kamal MA; Singh LR
CNS Neurol Disord Drug Targets; 2014; 13(7):1246-57. PubMed ID: 25230221
[TBL] [Abstract][Full Text] [Related]
9. Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms.
Röntgen A; Toprakcioglu Z; Tomkins JE; Vendruscolo M
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2313465121. PubMed ID: 38324572
[TBL] [Abstract][Full Text] [Related]
10. Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.
Bjørklund G; Hofer T; Nurchi VM; Aaseth J
J Inorg Biochem; 2019 Oct; 199():110717. PubMed ID: 31369907
[TBL] [Abstract][Full Text] [Related]
11. Gangliosides, α-Synuclein, and Parkinson's Disease.
Ledeen RW; Wu G
Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
[TBL] [Abstract][Full Text] [Related]
12. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
13. Targeting α-synuclein: Therapeutic options.
Dehay B; Decressac M; Bourdenx M; Guadagnino I; Fernagut PO; Tamburrino A; Bassil F; Meissner WG; Bezard E
Mov Disord; 2016 Jun; 31(6):882-8. PubMed ID: 26926119
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.
Alzghool OM; van Dongen G; van de Giessen E; Schoonmade L; Beaino W
Mov Disord; 2022 May; 37(5):936-948. PubMed ID: 35289424
[TBL] [Abstract][Full Text] [Related]
15. Alpha-Synuclein Autoimmune Decline in Prodromal Multiple System Atrophy and Parkinson's Disease.
Folke J; Bergholt E; Pakkenberg B; Aznar S; Brudek T
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742998
[TBL] [Abstract][Full Text] [Related]
16. Reactivity of copper-α-synuclein peptide complexes relevant to Parkinson's disease.
Dell'Acqua S; Pirota V; Anzani C; Rocco MM; Nicolis S; Valensin D; Monzani E; Casella L
Metallomics; 2015 Jul; 7(7):1091-102. PubMed ID: 25865825
[TBL] [Abstract][Full Text] [Related]
17. New insights into cellular α-synuclein homeostasis in health and disease.
Dettmer U; Selkoe D; Bartels T
Curr Opin Neurobiol; 2016 Feb; 36():15-22. PubMed ID: 26282834
[TBL] [Abstract][Full Text] [Related]
18. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.
Singh SK; Dutta A; Modi G
Future Med Chem; 2017 Jun; 9(10):1039-1053. PubMed ID: 28632413
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration.
Wang X; Becker K; Levine N; Zhang M; Lieberman AP; Moore DJ; Ma J
Acta Neuropathol Commun; 2019 Mar; 7(1):41. PubMed ID: 30871620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
